

Plasma pTau-217 in preclinical Alzheimer's disease

Erin M. Jonaitis, PhD^{1,2,3§}, Shorena Janelidze, PhD⁴, Karly A. Cody, BS², Rebecca Langhough Kosciak, PhD^{1,2,3}, Lianlian Du, MS^{2,5}, Nathaniel A. Chin, MD³, Niklas Mattsson-Carlgren, MD, PhD^{4,6,7}, Kirk J. Hogan, MD, JD⁸, Bradley T. Christian, PhD^{9,10}, Tobey J. Betthausen, PhD^{2,3}, Oskar Hansson, MD, PhD^{4,11†§}, Sterling C. Johnson^{12,1,2†}

§ Denotes corresponding author. † Denotes co-senior-authorship.

Erin M. Jonaitis: 600 Highland Avenue CSC K6/432 MC4670 Madison, WI 53792
(608) 262-1888 jonaitis@wisc.edu

Oskar Hansson: Clinical Memory Research Unit Department of Clinical Sciences
Malmö Skånes universitetssjukhus, VE Minnessjukdomar, 205 02 Malmö +46 72 226 7745
oskar.hansson@med.lu.se

Affiliations: 1) Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin – Madison, WI, USA 2) Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin – Madison, WI, USA 3) Department of Medicine, Division of Geriatrics and Gerontology, School of Medicine and Public Health, University of Wisconsin - Madison, WI, USA 4) Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden 5) Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin - Madison, WI, USA 6) Department of Neurology, Skåne University Hospital, Lund, Sweden 7) Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden 8) Department of Anesthesiology, School of Medicine and Public Health, University of Wisconsin – Madison, WI, USA 9) Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin - Madison, WI, USA 10) Department of

Psychiatry, School of Medicine and Public Health, University of Wisconsin - Madison, WI, USA 11) Skåne University Hospital, Malmö, Sweden 12) Geriatric Research Education and Clinical Center of the Wm. S. Middleton Memorial Veterans Hospital, Madison, WI, USA

Keywords: Alzheimer's disease, amyloid beta, cognitively unimpaired, plasma, p-tau217

Word count:

Abstract: 317

Body: 3255

Abstract

Background and Objectives: An accurate blood test for Alzheimer’s disease (AD) that is sensitive to preclinical proteinopathy and cognitive decline has clear implications for early detection and secondary prevention of AD. We assessed the performance of plasma pTau₂₁₇ against brain PET markers of amyloid ([¹¹C]-PiB) and tau ([¹⁸F]MK-6240), and its utility for predicting longitudinal cognition.

Methods: Samples were analyzed from a subset of participants with up to 8 years follow-up in the Wisconsin Registry for Alzheimer’s Prevention (WRAP; 2001-present; plasma 2011-present), a longitudinal cohort study of adults from midlife, enriched for parental history of AD. Participants were a convenience sample who volunteered for at least one PiB scan, had usable banked plasma, and were cognitively unimpaired at first plasma collection. Study personnel who interacted with participants or samples were blind to amyloid status. We used mixed effects models and receiver-operator characteristic curves to assess concordance between plasma pTau₂₁₇ and PET biomarkers of AD, and mixed effects models to understand the ability of plasma pTau₂₁₇ to predict longitudinal performance on WRAP’s preclinical Alzheimer’s cognitive composite (PACC-3).

Results: The primary analysis included 165 people (108 women; mean age=62.9 ± 6.06; 160 still enrolled; 2 deceased; 3 discontinued). Plasma pTau₂₁₇ was strongly related to PET-based estimates of concurrent brain amyloid ($\hat{\beta}_{DVR} = 0.83$ (0.75, 0.90), $p < .001$). Concordance was high between plasma pTau₂₁₇ and both amyloid PET (AUC=0.91, specificity=0.80, sensitivity=0.85, PPV=0.58, NPV=0.94, $LR^- = 5.48$) and tau PET (AUC=0.95, specificity=1, sensitivity=0.85, PPV=1, NPV=0.98, $LR^- = 6.47$). Higher baseline pTau₂₁₇

levels were associated with worse cognitive trajectories ($\hat{\beta}_{pTau \times age} = -0.07$ (-0.09, -0.06), $p < .001$).

Conclusions and Relevance: In a convenience sample of unimpaired adults, plasma pTau₂₁₇ levels correlate well with concurrent brain AD pathophysiology and with prospective cognitive performance. These data indicate that this marker can detect AD before clinical signs and thus may disambiguate presymptomatic AD from normal cognitive aging.

Classification of Evidence: This study meets Class III evidential criteria for diagnostic accuracy of plasma pTau₂₁₇.

Introduction

Blood-based biomarkers for Alzheimer's disease (AD) that detect beta-amyloid ($A\beta$) and phosphorylated tau (pTau) proteinopathy are rapidly developing.^{1,2} The utility and convenience of an accurate blood test has clear implications for accelerating and improving clinical research and practice.¹⁻⁴ Several candidate markers exist including mass-spectrometry⁵⁻⁷ and immunoassay⁸ measured $A\beta_{42}$ and $A\beta_{40}$ and their ratio, and phosphorylated tau at threonine 217 (pTau₂₁₇),⁹ 181 (pTau₁₈₁),¹⁰ and other phosphorylated sites,¹¹ as well as non-specific markers of neurodegeneration and astrogliosis, including neurofilament light (NFL)^{12,13} and glial fibrillary acidic protein (GFAP).¹⁴⁻¹⁶

Recently, interest has turned to pTau₂₁₇, as cerebrospinal fluid levels increase early in autosomal dominant AD¹⁷ and better discriminate AD from non-AD subgroups of cognitively impaired adults, compared to pTau₁₈₁.¹⁸ In plasma, pTau₂₁₇ accurately differentiates persons with neuropathologically defined AD from other dementia.^{9,19} Further, in vivo plasma pTau₂₁₇ levels correlate with ex vivo protein levels and spatial burden in post-mortem brain tissue.¹⁹⁻²¹ Next, plasma pTau₂₁₇ levels discriminate diagnostic groups informed by amyloid PET. pTau₂₁₇ levels are elevated among impaired (AD or mild cognitive impairment (MCI)) $A\beta^+$ participants compared to cognitively unimpaired (CU), $A\beta^-$ participants,^{11,19} and plasma pTau₂₁₇ and tau PET signal show moderate to high agreement.^{9,11,22} Serial plasma pTau₂₁₇ levels also differentiate AD from non-AD MCI, remaining stable and non-elevated in $A\beta^-$ patients, and increasing over time in $A\beta^+$ patients.²³

The utility of plasma pTau₂₁₇ to identify amyloid and tau proteinopathy in a preclinical cohort is less well studied. Among older adults in the Swedish BioFINDER study (mean age=72), pTau₂₁₇ levels increased over 6 years in A β ⁺ CU, but not A β ⁻,²³ similar to findings in MCI. In this same cohort, baseline pTau₂₁₇ levels affected cognitive change.³ In the Australian Imaging, Biomarker & Lifestyle study (AIBL), among CU adults (mean age=75), a twofold increase in levels of the pTau₂₁₇ + marker in A β ⁺ compared to A β ⁻ was recently reported,¹¹ although the correlation between this biomarker and A β centiloids was relatively weaker in CU than in AD and MCI, perhaps due to restriction of range (ρ = 0.64 vs. 0.45). In the Mayo Clinic Study of Aging, among CU adults (mean age=79), a smaller fold increase of 0.49 was reported in A β ⁺ compared to A β ⁻.²⁴ Measurement precision may depend in part on the instrument platform and assay.^{18,25,26}

Here we report a study from the Wisconsin Registry for Alzheimer's Prevention (WRAP)²⁷ in which we examine plasma pTau₂₁₇ trajectories in CU adults using Lilly's immunoassay for the Meso Scale Discovery platform (Lilly-MSD) [palmqvist_discriminative_2020]. For this study, participants had a mean age of 63 at first plasma collection. We examined A) whether changes in plasma pTau₂₁₇ levels over time track progression of AD proteinopathy ascertained from amyloid and tau positron emission tomography (PET) with [¹¹C]-PiB for amyloid and [¹⁸F]MK-6240 for tau; B) whether plasma pTau₂₁₇ levels accurately differentiate people with varying degrees of amyloid and tau burden; and C) whether plasma pTau₂₁₇ levels are associated with longitudinal cognition.

Methods

Ethics

The research protocol was approved by the University of Wisconsin-Madison Health Sciences IRB (IRB00000366), and all participants provided written informed consent.

Participants

Plasma samples were analyzed from WRAP participants with ≥ 1 amyloid PET scan using Pittsburgh Compound B (“PiB”; see Imaging methods). Participants were included in the PiB+ sample if they had ≥ 1 global PiB distribution volume ratio (DVR) > 1.19 (centiloid equivalent = 21.6). The PiB- sample included all participants who had ≥ 2 PiB scans with all global DVR ≤ 1.1 . We also examined samples from participants whose global PiB DVR trajectories indicated possible conversion from PiB- to PiB+ by virtue of initially low but recently subthreshold DVR values ($1.16 < \text{DVR} \leq 1.19$). Primary analyses included only participants who were cognitively unimpaired (CU) at their first plasma collection, and excluded one participant whose levels of pTau₂₁₇ were highly influential in models. Secondary analyses were conducted including these excluded participants (sensitivity set 1), and excluding participants with measured pTau₂₁₇ below the lower limit of detection (sensitivity set 2; see Plasma methods and Supplement).

Plasma methods

30 mL of blood were drawn from each participant into 3×10 mL lavender-top EDTA tubes (BD 366643; Franklin Lakes, New Jersey, United States). Samples were mixed gently by inverting 10-12 times and were centrifuged 15 minutes at 2000g at room temperature within 1 hour of collection. Plasma samples were aliquoted into 2 mL

cryovials (Wheaton Cryoelite W985863; Millville, New Jersey, United States). Aliquoted plasma was frozen at -80 °C within ninety minutes and stored for up to 10 years.

Plasma pTau₂₁₇ concentration was measured at the Clinical Memory Research Unit, Lund University (Sweden) using immunoassay on a Meso Scale Discovery (MSD) platform developed by Lilly Research Laboratories.⁹ Samples were assayed in duplicates according to published protocols²⁸ with biotinylated-IBA493 used as a capture antibody and SULFO-TAG-4G10-E2 as the detector. The assay was calibrated with a synthetic pTau₂₁₇ peptide. The mean intra-assay coefficient of variation (CV) was 7.11%. The inter-assay CV for 3 quality control samples included in every run was 10.3%. Plasma pTau₂₁₇ concentration was below the detection limit of the assay (0.11-0.17 pg/mL) for 6 cases. For each model, sensitivity analysis 2 excluded these observations. Samples were arranged on plates according to a randomization scheme devised by author EMJ, who had no contact with samples. All samples were analyzed by staff blind to clinical and imaging data.

Imaging methods

Participants underwent T1-weighted magnetic resonance imaging as well as amyloid ([¹¹C]-PiB) and tau ([¹⁸F]-MK-6240) PET imaging at the University of Wisconsin-Madison. Detailed methods for radioligand synthesis and PET and MRI acquisition, processing and quantification, and analysis were implemented as reported previously.^{29,30}

Amyloid burden was assessed as a global cortical average [¹¹C]-PiB DVR, and two DVR thresholds were applied for determining PiB positivity (PiB+): one at DVR > 1.19, based on previously published work,³¹ and another, lower threshold of DVR > 1.16 (corresponding to a centiloid of 17.7), previously shown to predict subsequent accumulation of amyloid.³² Estimated age of amyloid onset (EAOA) was obtained from

observed global PiB DVR using a combination of group-based trajectory modeling and Bayes' theorem³³ using either the most recent PET scan (for those who were PiB-) or the scan closest to the PiB+ threshold. Amyloid duration was then estimated as age at plasma sample minus EAOA and the corresponding estimated PiB DVR (GBTM-DVR) was calculated via linear transformation as described in Betthausen et al.³⁴ Centiloids were estimated from these DVRs according to the following equation: $CL = 148.33 \times DVR - 154.96$.

[¹⁸F]-MK-6240 standardized uptake volume ratio (SUVR) (70-90 minutes; cerebellum gray reference region excluding the superior medial vermis) tau burden was assessed visually by an expert reader (SCJ) using SUVR images overlaid on the coregistered MRI and scaled from 0-2.5. Images were classified as tau negative or tau positive for the medial temporal lobe (MTL; entorhinal cortex, amygdala or hippocampus) and for the neocortex (Neo; 1 or more cortical regions). The visual rating defined four classes: MK-, MK+ in MTL only, MK+ in neocortex only, and MK+ in MTL and neocortex.

Neuropsychological assessment and cognitive status

Participants in WRAP completed a comprehensive cognitive battery at each visit, including tests of memory, executive function, language ability, and other aspects of cognitive performance, alongside self- and informant-based measures of everyday functioning.²⁷ Based on these measures, participant cognitive status at each visit was determined via consensus conference.³⁵ Among those without clinically significant cognitive impairment (i.e., dementia or MCI), some were assigned a research diagnosis of "Cognitively Unimpaired-Declining" denoting performance within the range of normal, but suggestive of decline from baseline.³⁶

Our measure of global cognition was a three-test version of the Preclinical Alzheimer's Cognitive Composite³⁷ including the Rey Auditory-Verbal Learning Test, sum of Trials 1-5; the Wechsler Memory Scale Logical Memory II, total score; and the Wechsler Adult Intelligence Scale-Revised Digit Symbol Substitution, total score. Tests were combined by rescaling and computing an unweighted average, scaled such that first observations in cognitively unimpaired individuals were distributed $\sim N(0,1)$. The Wide-Range Achievement Test-Reading Subtest (standard score) was used as a measure of literacy.

Statistical analysis

Statistical analyses were performed in R 4.0.5.³⁸ Longitudinal pTau₂₁₇ trajectories were modeled using mixed effects models³⁹ with participant-level random intercepts, which are robust to missingness when data are missing at random. Two such models were fit. First, to evaluate how well pTau₂₁₇ measurements reflect brain amyloid, we estimated the fixed effect of GBTM-DVR at each timepoint. Second, to compare age trends in people known to be accumulating amyloid versus people who are not,²³ we estimated the fixed effects of age, amyloid status (PiB+ vs PiB-), and their interaction. Effect sizes were estimated by Ω^2 ,⁴⁰ where $0.01 \leq \Omega^2 < 0.06$ was considered a small effect size, $0.06 \leq \Omega^2 < 0.14$ medium, and $\Omega^2 \geq 0.14$ large.⁴¹ Test-retest reliability was assessed using the intraclass correlation.

To establish potential thresholds with maximal correspondence between pTau₂₁₇ and binary brain amyloid (global PiB) and tau (MTL+neocortical MK-6240) positivity, receiver-operator characteristic (ROC) curves⁴² were constructed on a sub-sample comprising 1 plasma observation per participant, acquired within 2 years of a PiB or MK-

6240 scan, respectively. Thresholds were selected to maximize Youden's index.⁴³ Positive and negative predictive values for PiB- and MK-positivity assumed population prevalence of 25% and 10%, respectively. In a secondary analysis, we used a robust norms approach to identify an alternate threshold for pTau₂₁₇ by first winnowing the sample to solidly PiB- individuals (DVR < 1.1 at all scans); computing the 2.5th and 97.5th percentiles; selecting all observations within this range; and recomputing the 97.5th percentile to obtain the robust-norms threshold. To validate these thresholds, we classified GBTM-DVR at each plasma observation into PiB- (GBTM-DVR ≤ 1.19) and PiB+ (GBTM-DVR > 1.19), and compared this against positivity on pTau₂₁₇ according to each threshold.

To evaluate the relationship between baseline pTau₂₁₇ and cognitive trajectories, we fit a mixed effects model of longitudinal PACC-3, with linear and quadratic age terms and their interaction with baseline pTau₂₁₇ modeled as continuous fixed effects, and a participant-level random intercept. Age and pTau₂₁₇ terms were mean-centered. Sex, education, baseline literacy, and number of prior exposures to the battery were included as covariates. For comparison, a covariates-only model was also fit.

To assess whether within-person change in pTau₂₁₇ predicts within-person change in cognition, and explore the phasing of this relationship, an exploratory, repeated measures correlation analysis was performed.^{44,45} This analysis used a subset of data in which pTau₂₁₇ was paired variously with concurrent PACC-3 scores and with PACC-3 lagged by one or two study visits. Only participants with at least four timepoints were included (N=46; N_{obs} = 93), to satisfy the constraints that each participant should contribute at least two pTau₂₁₇ observations, to assess within-person change, and that each such observation should allow for pairings with cognition under three lag conditions (e.g.,

pTau₂₁₇ at Visits 1 and 2 with PACC-3 at (A) Visits 1 & 2, (B) Visits 2 & 3, and (C) Visits 3 & 4, in successive models lag=0, lag=1, lag=2). This exploratory analysis was repeated twice, first using PACC-3 and pTau₂₁₇ values from which age had been partialled out, and then substituting GBTM-DVR for pTau₂₁₇.

Data availability

Coded data and R scripts underlying all analyses may be shared at the request of any qualified investigator for purposes of replication.

Results

Participants

173 participants had qualifying PiB scans and at least one plasma sample stored in EDTA. At their last PiB scan, 74 had PiB DVR > 1.19, and 99 had PiB DVR ≤ 1.19. Included in the second set were 84 having ≥ 2 PiB scans with all DVR ≤ 1.11, and 15 with values suggestive of possible conversion. From this set, 8 participants were removed from primary analyses due to cognitive impairment at first plasma (N=7), missing diagnosis at first plasma (N=1), or measured pTau₁₇₁ levels found to be highly influential (N=1). Participant characteristics for the primary analysis sample are shown in Table 1. For each applicable aim, excluded participants were included in a sensitivity analysis (sensitivity set 1; see eTable 1 and eFigures 1 and 3). 6 participants had pTau₁₇₁ levels below the lower limit of detection; these were excluded for a second sensitivity analysis (sensitivity set 2; see eTable 1 and eFigures 2 and 4).

Longitudinal pTau₂₁₇ trajectories

Individual pTau₂₁₇ trajectories are displayed by age in Figure 1A, and by GBTM-DVR in Figure 1B (secondary x-axis: centiloid conversions, at top). A strong relationship with

MK-6240 PET is evident: those with tau in both medial temporal and neocortical regions appear distinct from other groups. The improved alignment in Figure 1B supports strong correspondence between plasma pTau₂₁₇ and PiB PET.

The mixed effects models relating pTau₂₁₇ levels to GBM-DVR are shown in Table 2A. GBM-DVR was a strong predictor of measured pTau₂₁₇ ($\hat{\beta}_{\text{DVR}} = 0.83, \Omega^2 = 0.64$). Intraclass correlations were moderate. Together, the results indicate good test-retest reliability and high sensitivity to true underlying change. Results of sensitivity analyses were substantially similar.

The mixed effects models relating pTau₂₁₇ levels to age, with binary PiB status (PiB DVR > 1.19) as a moderator, are shown in Table 2B. A mid-sized, significant age by amyloid status interaction was observed such that levels of pTau₂₁₇ increased with age only in PiB+ participants, whereas in PiB- participants, the age-related slope estimate was indistinguishable from zero ($\hat{\beta}_{\text{PiB} \times \text{age}} = 0.021; \hat{\beta}_{\text{PiB-}} = 0.0016, \hat{\beta}_{\text{PiB+}} = 0.022; \Omega^2 = 0.11$). One participant with high pTau₂₁₇ levels continued to be highly influential in this model. The model fit to the primary dataset is shown in Figure 1C. Results of sensitivity analyses were similar.

pTau₂₁₇ threshold estimation

Boxplots and ROC curves relating pTau₂₁₇ to binary PiB and MTL+neocortical MK-6240 are shown in Figure 1D-G. Correspondence was high for both PiB positivity thresholds (early positivity (DVR > 1.16), AUC=0.90, PPV=0.58, NPV=0.94; late positivity (DVR > 1.19), AUC=0.91, PPV=0.58, NPV=0.94), as well as for MTL+neocortical MK-6240 positivity (AUC=0.95, PPV=1.00, NPV=0.98). Estimated thresholds were lower for amyloid

than tau (early PiB positivity: 0.27; late PiB positivity: 0.27; MTL+neocortical MK-6240 positivity: 0.37). Our robust norms threshold approach identified a higher pTau₂₁₇ positivity boundary of 0.37. Analyses on the sensitivity datasets were similar (see eFigures 1 and 2).

When adjudicating both the late PiB positivity, ROC-based threshold and the robust norms threshold against the ground truth of concurrent GBTM-DVR > 1.19, the ROC-based threshold was more sensitive, but less specific (ROC threshold: sensitivity = 0.91, specificity = 0.75; robust norms threshold: sensitivity = 0.7, specificity = 0.96). Among individuals having ≥ 1 plasma pTau₂₁₇ observation between these thresholds (N=70), half were PiB+ at their last PET scan (N=36).

Associations with longitudinal cognition

Figure 2A illustrates the mixed effects model relating baseline pTau₂₁₇ levels to PACC-3 trajectories. We observed a mid-sized, significant age by pTau₂₁₇ interaction ($\hat{\beta}_{\text{pTau}_{217} \times \text{age}} = -0.075, \Omega^2 = 0.10$). Lower baseline pTau₂₁₇ levels were associated with a flatter cognitive trajectory, whereas moderate and higher levels were linked to faster decline. According to this model, two women with average education, literacy, and prior exposure, but with 10th and 90th percentile levels of plasma pTau₂₁₇, would be expected to decline to a PACC-3 score of $z = -1.5$ by approximately ages 91.5 and 74.2, respectively; for similar men the expected ages are 86.4 and 71.7, respectively. A likelihood ratio test comparing this model to a covariates-only version indicated better performance when including pTau₂₁₇ ($\chi^2(3) = 70.7, p < .0001$). Model summaries are shown in Table 3. Sensitivity analyses were similar (see eTable 1 and eFigures 3 and 4).

Exploratory lagged repeated measures correlations on a subset of individuals with at least 4 observations (N=46) suggested weak within-person correspondence between pTau₂₁₇ and concurrent cognition ($r_{lag=0} = -0.130$), but stronger within-person relationships when a lag of 1 ($r_{lag=1} = -0.550$) or 2 visits ($r_{lag=2} = -0.670$; Figure 2B-D) was imposed. This pattern held when repeated measures correlation was performed instead after age had been partialled out from both pTau₂₁₇ and cognitive scores ($r_{lag=0} = -0.0720$; $r_{lag=1} = -0.500$; $r_{lag=2} = -0.630$). In comparison, relationships with modeled PiB DVR at the same lags were weaker ($r_{gbtm.lag=0} = -0.0230$; $r_{gbtm.lag=1} = -0.410$; $r_{gbtm.lag=2} = -0.540$).

Discussion

We characterized the temporal dynamics of Lilly-MSD pTau₂₁₇ in a cohort of late-middle-aged adults without baseline clinical cognitive impairment at a mean age of 63. We observed a strong relationship between brain amyloid positivity and pTau₂₁₇, with plasma biomarker trajectories rising with age only in A+ individuals. This is similar to a recent report from BioFINDER²³ in a sample approximately ten years older. We further observed strong relationships between pTau₂₁₇ trajectories and brain tau as measured via MK-6240: those with extensive tau deposition, all PiB+, exhibited increasing plasma levels of pTau₂₁₇. This resembles recent findings in AIBL of a moderately strong cross-sectional correlation between pTau₂₁₇ + and meta-temporal and mesial temporal MK-6240 SUVR in A+ older adults.¹¹ However, in that analysis, the correlation was weaker in a subset of CU participants, whereas in the present analysis, which includes only CU individuals and again features a cohort ten years younger, the relationship is strong.

Plasma biomarkers have potential for prescreening AD biomarker positive participants in clinical trials.³ To that end, our results are encouraging, as we observed strong relationships between plasma pTau₂₁₇ and concurrent brain imaging biomarkers of AD, with an AUC of approximately 0.91 for identifying PiB+ participants, and 0.95 for identifying those who were MK+. These values are similar to those seen for the easier task of discriminating AD A β ⁺ from CU A β ⁻ groups, and are high compared to other reports describing cognitively unimpaired elderly groups in AIBL,¹¹ MCSA,²⁴ and BioFINDER.⁴⁶ With our threshold for predicting PiB+, the PPV of pTau₂₁₇ was 0.58, which would reduce the number needed to screen to obtain a full sample. However, for other purposes, a more conservative threshold might be preferable. For MK, in contrast, the PPV of 1 and NPV of 0.98 are likely overestimates, but suggest this threshold may work well for many purposes, in principle, in populations with prevalence close to our estimates.

Our two analyses relating baseline pTau₂₁₇ to PACC-3 scores were complementary, each suggesting important longitudinal relationships between this plasma biomarker and cognition. In our primary analysis, the pTau₂₁₇ by age interaction suggests those with higher baseline biomarker levels evince worse cognitive trajectories with age than do those with lower biomarker levels, whose cognitive trajectories appear flat. In our exploratory analysis using repeated measures correlation, although the within-person relationship between biomarker levels and concurrent cognitive performance is weak, by modeling a delayed effect using a lagged correlation, a robust negative relationship emerges. Although similar relationships have been found in older groups, our report establishes such relationships with biomarkers measured in late midlife.^{3,23,24} Given the interest in

establishing valid surrogate outcomes for AD pharmaceutical research,⁴⁷ our findings may inform the trial design in which the fitness of plasma pTau₂₁₇ for that purpose is evaluated.

Limitations

The chief limitation of the present analysis is our small, racially-homogenous sample, drawn from a cohort that is convenience- and not population-based.²⁷ The complexities of bringing plasma assays into use with heterogenous clinical populations should not be discounted. However, recent work in WHICAP suggests relatively good concordance between pTau₂₁₇ and clinical status, and no evident demographic biases.⁴⁸ Future directions include assaying our extensive back-catalog of plasma and expanding our existing cohort with a more diverse group of research participants.

Conclusion

In this report, we extend previous findings of strong relationships between plasma levels of pTau₂₁₇, concurrent PET AD biomarkers, and prospective cognition to a preclinical dataset. These findings have strong implications for early detection, which is prerequisite for several major goals of AD research: understanding susceptibility and resilience factors that underlie prognosis; designing better primary and secondary AD prevention trials; and determining the relative timing and impact of AD and co-occurring pathologies on cognitive decline.

Acknowledgements and Disclosures

OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Fujirebio, Genentech, Novartis, Roche, and Siemens. SCJ

has served as a consultant to Eisai and Roche Diagnostics, has received an equipment grant from Roche Diagnostics, and has received support (sponsoring of an observational study and provision of precursor for tau imaging) from Cerveau Technologies. Authors EMJ, SJ, KAC, RLK, LD, NAC, NMC, KJH, BTC, and TJB have nothing to disclose.

Work at the University of Wisconsin was supported by NIH R01AG027161 (Johnson), NIH R01AG021155 (Johnson), AARF 19614533 (Betthausen), S10 OD025245-01 (Christian) and the University of Wisconsin Institute for Clinical and Translational Research NIH UL1TR002375 (Cody). We extend our deepest thanks to the WRAP participants and staff for their invaluable contributions to the study.

Work at Lund University was supported by the Swedish Research Council (2016-00906), the Knut and Alice Wallenberg foundation (2017-0383), the Marianne and Marcus Wallenberg foundation (2015.0125), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-939932), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1280/20), the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-0000028), Regionalt Forskningsstöd (2020-0314) and the Swedish federal government under the ALF agreement (2018-Projekt0279).

References

1. Hansson O. Biomarkers for neurodegenerative diseases. *Nature Medicine*. 2021;27(6):954-963. doi:[10.1038/s41591-021-01382-x](https://doi.org/10.1038/s41591-021-01382-x)
2. Leuzy A, Mattsson-Carlgrén N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer's disease. *EMBO molecular medicine*. 2022;14(1):e14408. doi:[10.15252/emmm.202114408](https://doi.org/10.15252/emmm.202114408)
3. Cullen NC, Leuzy A, Janelidze S, et al. Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly. January 2021:2021.01.22.21250293. doi:[10.1101/2021.01.22.21250293](https://doi.org/10.1101/2021.01.22.21250293)
4. Bateman RJ, Blennow K, Doody R, et al. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. *The Journal of Prevention of Alzheimer's Disease*. 2019;6(3):169-173. doi:[10.14283/jpad.2019.21](https://doi.org/10.14283/jpad.2019.21)
5. West T, Kirmess KM, Meyer MR, et al. A blood-based diagnostic test incorporating plasma A β 42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: Findings from a multi cohort validity analysis. *Molecular Neurodegeneration*. 2021;16(1):30. doi:[10.1186/s13024-021-00451-6](https://doi.org/10.1186/s13024-021-00451-6)
6. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2017;13(8):841-849. doi:[10.1016/j.jalz.2017.06.2266](https://doi.org/10.1016/j.jalz.2017.06.2266)
7. Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature*. 2018;554(7691):249-254. doi:[10.1038/nature25456](https://doi.org/10.1038/nature25456)
8. Palmqvist S, Janelidze S, Stomrud E, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β -Amyloid Status. *JAMA neurology*. 2019;76(9):1060-1069. doi:[10.1001/jamaneurol.2019.1632](https://doi.org/10.1001/jamaneurol.2019.1632)
9. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*. 2020;324(8):1-11. doi:[10.1001/jama.2020.12134](https://doi.org/10.1001/jama.2020.12134)
10. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. *The Lancet Neurology*. 2020;19(5):422-433. doi:[10.1016/S1474-4422\(20\)30071-5](https://doi.org/10.1016/S1474-4422(20)30071-5)
11. Doré V, Doecke JD, Saad ZS, et al. Plasma P217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. *Alzheimer's & Dementia (Amsterdam, Netherlands)*. 2022;14(1):e12307. doi:[10.1002/dad2.12307](https://doi.org/10.1002/dad2.12307)

12. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. *JAMA neurology*. 2019;76(7):791-799. doi:[10.1001/jamaneurol.2019.0765](https://doi.org/10.1001/jamaneurol.2019.0765)
13. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nature Communications*. 2021;12(1):3400. doi:[10.1038/s41467-021-23620-z](https://doi.org/10.1038/s41467-021-23620-z)
14. Elahi FM, Casaletto KB, La Joie R, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2020;16(4):681-695. doi:[10.1016/j.jalz.2019.09.004](https://doi.org/10.1016/j.jalz.2019.09.004)
15. Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid- β but not tau pathology in Alzheimer's disease. *Brain: A Journal of Neurology*. 2021;144(11):3505-3516. doi:[10.1093/brain/awab223](https://doi.org/10.1093/brain/awab223)
16. Benedet AL, Milà-Alomà M, Vrillon A, et al. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. *JAMA neurology*. 2021;78(12):1471-1483. doi:[10.1001/jamaneurol.2021.3671](https://doi.org/10.1001/jamaneurol.2021.3671)
17. Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*. 2020;26(3):398-407. doi:[10.1038/s41591-020-0781-z](https://doi.org/10.1038/s41591-020-0781-z)
18. Karikari TK, Emeršič A, Vrillon A, et al. Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. *Alzheimer's & Dementia*. 2021;17(5):755-767. doi:[10.1002/alz.12236](https://doi.org/10.1002/alz.12236)
19. Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. *The Lancet Neurology*. 2021;20(9):739-752. doi:[10.1016/S1474-4422\(21\)00214-3](https://doi.org/10.1016/S1474-4422(21)00214-3)
20. Wennström M, Janelidze S, Nilsson KPR, et al. Cellular localization of p-Tau217 in brain and its association with p-Tau217 plasma levels. *Acta Neuropathologica Communications*. 2022;10(1):3. doi:[10.1186/s40478-021-01307-2](https://doi.org/10.1186/s40478-021-01307-2)
21. Mattsson-Carlgrén N, Janelidze S, Bateman RJ, et al. Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. *EMBO molecular medicine*. 2021;13(6):e14022. doi:[10.15252/emmm.202114022](https://doi.org/10.15252/emmm.202114022)

22. Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. *JAMA neurology*. 2021;78(2):149-156. doi:[10.1001/jamaneurol.2020.4201](https://doi.org/10.1001/jamaneurol.2020.4201)
23. Mattsson-Carlgrén N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-Tau217 is increased in early stages of Alzheimer's disease. *Brain: A Journal of Neurology*. 2020;143(11):3234-3241. doi:[10.1093/brain/awaa286](https://doi.org/10.1093/brain/awaa286)
24. Mielke MM, Frank RD, Dage JL, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. *JAMA neurology*. 2021;78(9):1108-1117. doi:[10.1001/jamaneurol.2021.2293](https://doi.org/10.1001/jamaneurol.2021.2293)
25. Triana-Baltzer G, Moughadam S, Slemmon R, et al. Development and validation of a high-sensitivity assay for measuring P217+tau in plasma. *Alzheimer's & Dementia (Amsterdam, Netherlands)*. 2021;13(1):e12204. doi:[10.1002/dad2.12204](https://doi.org/10.1002/dad2.12204)
26. Barthélemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. *The Journal of Experimental Medicine*. 2020;217(11):e20200861. doi:[10.1084/jem.20200861](https://doi.org/10.1084/jem.20200861)
27. Johnson SC, Kosciak RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. *Alzheimer's & Dementia (Amsterdam, Netherlands)*. 2018;10:130-142. doi:[10.1016/j.dadm.2017.11.007](https://doi.org/10.1016/j.dadm.2017.11.007)
28. Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β 42/A β 40 and p-tau. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*. 2022;18(2):283-293. doi:[10.1002/alz.12395](https://doi.org/10.1002/alz.12395)
29. Johnson SC, Christian BT, Okonkwo OC, et al. Amyloid burden and neural function in people at risk for Alzheimer's Disease. *Neurobiology of aging*. 2014;35(3):576-584. doi:[10.1016/j.neurobiolaging.2013.09.028](https://doi.org/10.1016/j.neurobiolaging.2013.09.028)
30. Betthausen TJ, Cody KA, Zammit MD, et al. In Vivo Characterization and Quantification of Neurofibrillary Tau PET Radioligand 18F-MK-6240 in Humans from Alzheimer Disease Dementia to Young Controls. *Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine*. 2019;60(1):93-99. doi:[10.2967/jnumed.118.209650](https://doi.org/10.2967/jnumed.118.209650)
31. Racine AM, Clark LR, Berman SE, et al. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease. *Journal of Alzheimer's disease : JAD*. 2016;54(4):1395-1408. doi:[10.3233/JAD-160528](https://doi.org/10.3233/JAD-160528)
32. Farrell ME, Jiang S, Schultz AP, et al. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. *Neurology*. 2021;96(4):e619-e631. doi:[10.1212/WNL.0000000000011214](https://doi.org/10.1212/WNL.0000000000011214)

33. Kosciak RL, Betthausen TJ, Jonaitis EM, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2020;12(1). doi:[10.1002/dad2.12007](https://doi.org/10.1002/dad2.12007)
34. Betthausen TJ, Bilgel M, Kosciak RL, et al. Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts. December 2021:2021.12.02.21266523. doi:[10.1101/2021.12.02.21266523](https://doi.org/10.1101/2021.12.02.21266523)
35. Kosciak RL, La Rue A, Jonaitis EM, et al. Emergence of mild cognitive impairment in late middle-aged adults in the Wisconsin Registry for Alzheimer's Prevention. *Dementia and Geriatric Cognitive Disorders*. 2014;38(1-2):16-30. doi:[10.1159/000355682](https://doi.org/10.1159/000355682)
36. Langhough Kosciak R, Hermann BP, Allison S, et al. Validity Evidence for the Research Category, "Cognitively Unimpaired - Declining," as a Risk Marker for Mild Cognitive Impairment and Alzheimer's Disease. *Frontiers in Aging Neuroscience*. 2021;13:688478. doi:[10.3389/fnagi.2021.688478](https://doi.org/10.3389/fnagi.2021.688478)
37. Jonaitis EM, Kosciak RL, Clark LR, et al. Measuring longitudinal cognition: Individual tests versus composites. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*. 2019;11:74-84. doi:[10.1016/j.dadm.2018.11.006](https://doi.org/10.1016/j.dadm.2018.11.006)
38. R Core Team. R: A Language and Environment for Statistical Computing. 2017.
39. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *Journal of Statistical Software*. 2015;67(1):1-48. doi:[10.18637/jss.v067.i01](https://doi.org/10.18637/jss.v067.i01)
40. Xu R. Measuring explained variation in linear mixed effects models. *Statistics in Medicine*. 2003;22(22):3527-3541. doi:[10.1002/sim.1572](https://doi.org/10.1002/sim.1572)
41. Ben-Shachar MS, Lüdtke D, Makowski D. effectsize: Estimation of effect size indices and standardized parameters. *Journal of Open Source Software*. 2020;5(56):2815. doi:[10.21105/joss.02815](https://doi.org/10.21105/joss.02815)
42. Robin X, Turck N, Hainard A, et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*. 2011;12:77.
43. Youden WJ. Index for rating diagnostic tests. *Cancer*. 1950;3(1):32-35. doi:[10.1002/1097-0142\(1950\)3:1<32::aid-cncr2820030106>3.0.co;2-3](https://doi.org/10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3)
44. Bakdash JZ, Marusich LR. Repeated Measures Correlation. *Frontiers in Psychology*. 2017;8:456. doi:[10.3389/fpsyg.2017.00456](https://doi.org/10.3389/fpsyg.2017.00456)
45. Bakdash JZ, Marusich LR. *Rmcorr: Repeated Measures Correlation*; 2021.
46. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA*. 2020;324(8):772-781. doi:[10.1001/jama.2020.12134](https://doi.org/10.1001/jama.2020.12134)

47. Planche V, Villain N. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? *JAMA neurology*. 2021;78(11):1307-1308. doi:[10.1001/jamaneurol.2021.3126](https://doi.org/10.1001/jamaneurol.2021.3126)
48. Brickman AM, Manly JJ, Honig LS, et al. Correlation of plasma and neuroimaging biomarkers in Alzheimer's disease. *Annals of Clinical and Translational Neurology*. March 2022. doi:[10.1002/acn3.51529](https://doi.org/10.1002/acn3.51529)

Table 1

Demographics and background characteristics of primary analysis sample.

Variable	Value
Number of participants	165
Number of plasma observations per participant, median (range)	3 (1-5)
Age at first plasma, mean (SD)	62.94 (6.06)
Age at last plasma, mean (SD)	68.22 (6.10)
Years of plasma follow-up, mean (SD)	5.28 (1.62)
Female, N (%)	108 (65%)
White, N (%)	158 (96%)
Black, N (%)	4 (2%)
Native American, N (%)	3 (2%)
Cognitively unimpaired-stable at first plasma, N (%)	131 (79%)
Cognitively unimpaired-declining at first plasma, N (%)	34 (21%)
Cognitively unimpaired-stable at last plasma, N (%)	134 (81%)
Cognitively unimpaired-declining at last plasma, N (%)	23 (14%)
MCI at last plasma, N (%)	7 (4%)
Dementia at last plasma, N (%)	1 (1%)
PiB- at last plasma, N (%)	95 (58%)
PiB+ at last plasma, N (%)	70 (42%)
MK- at last plasma, N (%)	111 (67%)
MK+ MTL only at last plasma, N (%)	6 (4%)
MK+ Neo only at last plasma, N (%)	2 (1%)
MK+ MTL+Neo at last plasma, N (%)	26 (16%)
MK+ missing, N (%)	20 (12%)

St

Table 2

Results of linear mixed effect models of pTau₂₁₇. Each model included a per-participant random intercept. For each, sensitivity analysis 1 included observations from eight additional participants who were either cognitively unimpaired or missing a cognitive diagnosis at first available plasma draw (N=7) or whose pTau₂₁₇ values were highly influential (N=1), and sensitivity analysis 2 excluded six single observations on five participants for which measured pTau₂₁₇ values fell below the lower limit of detection. (A) pTau₂₁₇ as a function of GBTM-DVR. (B) pTau₂₁₇ as a function of age, moderated by binary PiB status.

(2A) <i>Predictors</i>	Primary set			Sensitivity set 1			Sensitivity set 2		
	<i>Estimates</i>	<i>CI</i>	<i>p</i>	<i>Estimates</i>	<i>CI</i>	<i>p</i>	<i>Estimates</i>	<i>CI</i>	<i>p</i>
Intercept	0.00	-0.08 – 0.08	0.968	0.00	-0.12 – 0.12	0.972	0.00	-0.08 – 0.08	0.984
GBTM-DVR	0.83	0.75 – 0.90	<0.001	0.46	0.35 – 0.56	<0.001	0.83	0.75 – 0.90	<0.001
Random Effects									
σ^2	0.12			0.32			0.12		
τ_{00}	0.25 <small>Reggieid</small>			0.52 <small>Reggieid</small>			0.25 <small>Reggieid</small>		
ICC	0.67			0.62			0.67		
N	165 <small>Reggieid</small>			173 <small>Reggieid</small>			165 <small>Reggieid</small>		
Observations	515			530			509		
Marginal R ² / Conditional R ²	0.648 / 0.885			0.200 / 0.695			0.649 / 0.885		

(2B) <i>Predictors</i>	Primary set			Sensitivity set 1			Sensitivity set 2		
	<i>Estimates</i>	<i>CI</i>	<i>p</i>	<i>Estimates</i>	<i>CI</i>	<i>p</i>	<i>Estimates</i>	<i>CI</i>	<i>p</i>
Intercept	0.23	0.20 – 0.27	<0.001	0.27	0.21 – 0.34	<0.001	0.23	0.20 – 0.27	<0.001
Amyloid positivity	0.19	0.13 – 0.24	<0.001	0.16	0.06 – 0.26	0.002	0.19	0.13 – 0.24	<0.001
Age [centered], linear	0.00	-0.00 – 0.00	0.337	0.00	-0.00 – 0.01	0.267	0.00	-0.00 – 0.00	0.350
Amyloid positivity x Age [centered], linear	0.02	0.02 – 0.03	<0.001	0.01	0.00 – 0.03	0.021	0.02	0.02 – 0.03	<0.001
Random Effects									
σ^2	0.01			0.05			0.01		
τ_{00}	0.03 <small>Reggieid</small>			0.09 <small>Reggieid</small>			0.03 <small>Reggieid</small>		
ICC	0.81			0.66			0.81		
N	165 <small>Reggieid</small>			173 <small>Reggieid</small>			165 <small>Reggieid</small>		
Observations	515			530			509		
Marginal R ² / Conditional R ²	0.355 / 0.879			0.093 / 0.695			0.356 / 0.878		

Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

Table 3

Results of linear mixed effect models of PACC-3 as a function of (1) covariates only (sex, education, baseline literacy, and age); (2) covariates plus baseline pTau₂₁₇ and its interaction with age. In both models, age was modeled as a second-degree polynomial. Models included a per-participant random intercept.

<i>Predictors</i>	Base model			With pTau217		
	<i>Estimates</i>	<i>CI</i>	<i>p</i>	<i>Estimates</i>	<i>CI</i>	<i>p</i>
Intercept	-3.71	-5.43 -- 1.99	<0.001	-4.14	-5.83 -- 2.44	<0.001
Sex [Male]	-0.41	-0.69 -- 0.13	0.004	-0.49	-0.77 -- 0.22	0.001
Education [Years]	0.09	0.01 – 0.16	0.024	0.10	0.03 – 0.17	0.007
Baseline literacy	0.02	0.00 – 0.04	0.026	0.02	0.00 – 0.04	0.015
Practice	0.12	0.05 – 0.19	0.001	0.14	0.07 – 0.21	<0.001
Age [centered], linear	-0.07	-0.10 -- 0.05	<0.001	-0.09	-0.11 -- 0.06	<0.001
Age [centered], quadratic	-0.00	-0.00 -- 0.00	0.001	-0.00	-0.00 -- 0.00	0.015
Baseline pTau217				-0.07	-0.25 – 0.11	0.466
Baseline pTau217 x Age [centered], linear				-0.07	-0.09 -- 0.06	<0.001
Baseline pTau217 x Age [centered], quadratic				-0.00	-0.00 – 0.00	0.666
Random Effects						
σ^2	0.24			0.20		
τ_{00}	0.64	Reggieid		0.63	Reggieid	
ICC	0.73			0.76		
N	165	Reggieid		165	Reggieid	
Observations	509			509		
Marginal R ² / Conditional R ²	0.237 / 0.793			0.330 / 0.840		

Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

Figure Captions

Figure 1. Longitudinal plasma pTau217. Observations from a single participant are shown with connected edges. (A) Plasma pTau217 as a function of age at blood draw. Color indicates the extent of tau burden as indicated on tau PET. (B) Plasma pTau217 as a function of estimated PiB DVR at the time of plasma acquisition. Color indicates the extent of tau burden as indicated on tau PET. (C) Plasma pTau217 as a function of age at blood draw. Color indicates amyloid PET positivity. Lines with shaded confidence bands represent slope estimates from a linear mixed effects model of pTau217 as a function of the interaction of age and amyloid positivity.

Figure 2. Relationship between pTau217 and PET AD biomarkers. (A) Distribution of pTau217 among PiB- and PiB+ participants. (B) Receiver-operator characteristic (ROC) curve relating pTau217 to binary PiB status. Two positivity thresholds were considered for PiB: global DVR > 1.19 (red) and global DVR > 1.16 (blue). (C) Distribution of pTau217 among MK- and MK+ participants. (D) ROC curve relating pTau217 to binary MK status. Scans were marked as MK+ if tracer binding was evident in both medial temporal lobe and neocortex, and MK- otherwise.

Figure 3. Relationships between pTau217 and longitudinal cognition. (A) Global cognition (PACC-3) as a function of age and baseline pTau217 level. Low, medium, and high pTau217 values reflect the 10th, 50th, and 90th sample percentiles. (B-D) Repeated measures correlation between global cognition (PACC-3) and pTau217 with lags of 0 (B), 1 (C), and 2 (D) visits between biomarker and cognitive test. The steeper slope in the rightmost panel suggests a stronger negative relationship between earlier pTau217 and downstream PACC-3.

Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

Jonaitis: Plasma p-tau₂₁₇ in preclinical Alzheimer's disease

Supplement

eTable 1

Results of linear mixed effect models of PACC-3 as a function of covariates plus baseline plasma pTau₂₁₇ and its interaction with age, in two sensitivity sets. The first sensitivity set includes the primary analysis set plus eight additional participants who were cognitively impaired at first plasma draw (N=6), who did not have a consensus diagnosis at this visit (N=1) or who had extreme values of pTau₂₁₇ (N=1). The second sensitivity set includes the primary analysis set, minus 6 observations on 5 participants for which the observed pTau₂₁₇ values were below the lower limit of detection. In both models, age was modeled as a second-degree polynomial. Models included a per-participant random intercept.

<i>Predictors</i>	Sensitivity set 1			Sensitivity set 2		
	<i>Estimates</i>	<i>CI</i>	<i>p</i>	<i>Estimates</i>	<i>CI</i>	<i>p</i>
Intercept	-4.24	-5.89 -- 2.60	<0.001	-4.14	-5.84 -- 2.45	<0.001
Sex [Male]	-0.55	-0.83 -- 0.26	<0.001	-0.49	-0.76 -- 0.21	0.001
Education [Years]	0.08	0.00 – 0.15	0.041	0.10	0.03 – 0.18	0.006
Baseline literacy	0.03	0.01 – 0.04	0.003	0.02	0.00 – 0.04	0.017
Practice	0.15	0.08 – 0.21	<0.001	0.14	0.08 – 0.21	<0.001
Age [centered], linear	-0.17	-0.31 -- 0.03	0.020	-0.05	-0.23 – 0.14	0.623
Age [centered], quadratic	-0.08	-0.11 -- 0.06	<0.001	-0.09	-0.11 -- 0.06	<0.001

Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

Baseline pTau217	-0.00	-0.00 -- 0.00	0.001	-0.00	-0.00 -- 0.00	0.027
Baseline pTau217 x Age [centered], linear	-0.06	-0.07 -- 0.04	<0.001	-0.08	-0.09 -- 0.06	<0.001
Baseline pTau217 x Age [centered], quadratic	-0.00	-0.00 -- 0.00	0.049	-0.00	-0.00 -- 0.00	0.524
Random Effects						
σ^2	0.20			0.20		
τ_{00}	0.69	Reggieid		0.63	Reggieid	
ICC	0.77			0.76		
N	172	Reggieid		165	Reggieid	
Observations	523			503		
Marginal R ² / Conditional R ²	0.345 / 0.851			0.332 / 0.842		

Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

Figure Captions


Figure 1. Longitudinal plasma pTau217. Observations from a single participant are shown with connected edges. (A) Plasma pTau217 as a function of age at blood draw. Color indicates the extent of tau burden as indicated on tau PET. (B) Plasma pTau217 as a function of estimated PiB DVR at the time of plasma acquisition. Color indicates the extent of tau burden as indicated on tau PET. (C) Plasma pTau217 as a function of age at blood draw. Color indicates amyloid PET positivity. Lines with shaded confidence bands represent slope estimates from a linear mixed effects model of pTau217 as a function of the interaction of age and amyloid positivity.

Figure 2. Relationship between pTau217 and PET AD biomarkers. (A) Distribution of pTau217 among PiB- and PiB+ participants. (B) Receiver-operator characteristic (ROC) curve relating pTau217 to binary PiB status. Two positivity thresholds were considered for PiB: global DVR > 1.19 (red) and global DVR > 1.16 (blue). (C) Distribution of pTau217 among MK- and MK+ participants. (D) ROC curve relating pTau217 to binary MK status. Scans were marked as MK+ if tracer binding was evident in both medial temporal lobe and neocortex, and MK- otherwise.

Figure 3. Relationships between pTau217 and longitudinal cognition. (A) Global cognition (PACC-3) as a function of age and baseline pTau217 level. Low, medium, and high pTau217 values reflect the 10th, 50th, and 90th sample percentiles. (B-D) Repeated measures correlation between global cognition (PACC-3) and pTau217 with lags of 0 (B), 1 (C), and 2 (D) visits between biomarker and cognitive test. The steeper slope in the rightmost panel suggests a stronger negative relationship between earlier pTau217 and downstream PACC-3.


Jonaitis: Plasma p-tau₂₁₇ in preclinical Alzheimer's disease

Figure 1




Jonaitis: Plasma p-tau₂₁₇ in preclinical Alzheimer's disease

Figure 2



Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

Figure 3



Jonaitis: Plasma p-tau₂₁₇ in preclinical Alzheimer's disease

eFigure Captions

eFigure 1. Longitudinal plasma pTau₂₁₇, sensitivity set 1 (including 6 participants who were cognitively impaired at baseline; one with no baseline diagnosis; and one influential pTau₂₁₇ observation). Observations from a single participant are shown with connected edges. (A) Plasma pTau₂₁₇ as a function of age at blood draw. Color indicates the extent of tau burden as indicated on tau PET. (B) Plasma pTau₂₁₇ as a function of estimated PiB DVR at the time of plasma acquisition. Color indicates the extent of tau burden as indicated on tau PET. (C) Plasma pTau₂₁₇ as a function of age at blood draw. Color indicates amyloid PET positivity. Lines with shaded confidence bands represent slope estimates from a linear mixed effects model of pTau₂₁₇ as a function of the interaction of age and amyloid positivity. (D) Distribution of pTau₂₁₇ among PiB- and PiB+ participants. (E) Receiver-operator characteristic (ROC) curve relating pTau₂₁₇ to binary PiB status. Two positivity thresholds were considered for PiB: global DVR > 1.19 (red) and global DVR > 1.16 (blue). (F) Distribution of pTau₂₁₇ among MK- and MK+ participants. (G) ROC curve relating pTau₂₁₇ to binary MK status. Scans were marked as MK+ if tracer binding was evident in both medial temporal lobe and neocortex, and MK- otherwise.

eFigure 2. Longitudinal plasma pTau₂₁₇, sensitivity set 2 (excluding 6 observations from 5 participants in which the pTau₂₁₇ value fell below the lower limit of detection). Observations from a single participant are shown with connected edges. (A) Plasma pTau₂₁₇ as a function of age at blood draw. Color indicates the extent of tau burden as indicated on tau PET. (B) Plasma pTau₂₁₇ as a function of estimated PiB DVR at the time of plasma acquisition. Color indicates the extent of tau burden as indicated on tau PET. (C)

Jonaitis: Plasma p-tau₂₁₇ in preclinical Alzheimer's disease

Plasma pTau₂₁₇ as a function of age at blood draw. Color indicates amyloid PET positivity.

Lines with shaded confidence bands represent slope estimates from a linear mixed effects model of pTau₂₁₇ as a function of the interaction of age and amyloid positivity. (D)


Distribution of pTau₂₁₇ among PiB- and PiB+ participants. (E) Receiver-operator characteristic (ROC) curve relating pTau₂₁₇ to binary PiB status. Two positivity thresholds were considered for PiB: global DVR > 1.19 (red) and global DVR > 1.16 (blue). (F)

Distribution of pTau₂₁₇ among MK- and MK+ participants. (G) ROC curve relating pTau₂₁₇ to binary MK status. Scans were marked as MK+ if tracer binding was evident in both medial temporal lobe and neocortex, and MK- otherwise.


eFigure 3. Relationships between pTau₂₁₇ and longitudinal cognition, sensitivity set 1 (including 6 participants who were cognitively impaired at baseline; one with no baseline diagnosis; and one influential pTau₂₁₇ observation). Global cognition (PACC-3) as a function of age and baseline pTau₂₁₇ level. Low, medium, and high pTau₂₁₇ values reflect the 10th, 50th, and 90th sample percentiles.

eFigure 4. Relationships between pTau₂₁₇ and longitudinal cognition, sensitivity set 2 (excluding 6 observations from 5 participants in which the pTau₂₁₇ value fell below the lower limit of detection). Global cognition (PACC-3) as a function of age and baseline pTau₂₁₇ level. Low, medium, and high pTau₂₁₇ values reflect the 10th, 50th, and 90th sample percentiles.

eFigure 1




eFigure 2



Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

eFigure 3



Jonaitis: Plasma p-tau217 in preclinical Alzheimer's disease

eFigure 4

